U.S. markets closed

Allakos Inc. (ALLK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
100.54-0.10 (-0.10%)
At close: 4:00PM EDT

100.54 0.00 (0.00%)
After hours: 4:20PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close100.64
Open99.49
Bid84.00 x 900
Ask156.00 x 900
Day's Range97.22 - 101.76
52 Week Range62.34 - 157.98
Volume82,349
Avg. Volume210,627
Market Cap5.386B
Beta (5Y Monthly)0.90
PE Ratio (TTM)N/A
EPS (TTM)-3.58
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est136.63
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Allakos Reports First Quarter 2021 Financial Results and Provides Business Update
    GlobeNewswire

    Allakos Reports First Quarter 2021 Financial Results and Provides Business Update

    REDWOOD CITY, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the first quarter ended March 31, 2021 and provided a business update. Recent Accomplishments Announced the acceptance of two oral and five poster presentations at the Digestive Disease Week (DDW) Annual Meeting taking place May 21 to 23, 2021. ePosters and ePapers will be available from the DDW ePosters and ePapers website. Abstracts can now be found here.Initiated a randomized, double-blind, placebo-controlled Phase 3 study of lirentelimab in patients with eosinophilic duodenitis. Upcoming 2021 Milestones Topline data from a randomized, double-blind, placebo-controlled Phase 3 study of lirentelimab in patients with eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) expected in the fourth quarter of 2021.Topline data from a randomized, double-blind, placebo-controlled Phase 2/3 study of lirentelimab in patients with eosinophilic esophagitis (EoE) expected in the fourth quarter of 2021.Initiation of a randomized, double-blind, placebo-controlled Phase 2/3 study of subcutaneous lirentelimab in patients with EG and/or EoD expected in the second half of 2021.Initiation of a Phase 2 study in a non eosinophilic gastrointestinal disease in the second half of 2021. First Quarter 2021 Financial Results Research and development expenses were $38.9 million in the first quarter of 2021 as compared to $18.3 million in the same period in 2020, an increase of $20.6 million. General and administrative expenses were $16.7 million in the first quarter of 2021 as compared to $11.6 million in the same period in 2020, an increase of $5.1 million. Allakos reported a net loss of $55.6 million in the first quarter of 2021 as compared to $27.8 million in the same period in 2020, an increase of $27.8 million. Net loss per basic and diluted share was $1.04 for the first quarter of 2021 compared to $0.57 in the same period in 2020. Allakos ended the first quarter of 2021 with $615.9 million in cash, cash equivalents and marketable securities. About Allakos Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company’s lead antibody, lirentelimab (AK002), is being evaluated in a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and a Phase 2/3 study in eosinophilic esophagitis (EoE). Lirentelimab targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Lirentelimab has been tested in multiple clinical studies. In these studies, lirentelimab eliminated blood and tissue eosinophils, inhibited mast cells and improved disease symptoms in patients with EG and/or EoD, EoE, mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria and indolent systemic mastocytosis. For more information, please visit the Company's website at www.allakos.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, Allakos’ progress and business plans, the expected timing of anticipated study results and plans relating to its future clinical trials. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to: Allakos’ stages of clinical drug development; Allakos’ ability to timely complete clinical trials for, and if approved, commercialize lirentelimab (AK002), its lead compound; Allakos’ ability to obtain required regulatory approvals for its product candidates; uncertainties related to the enrollment of patients in its clinical trials; Allakos’ ability to demonstrate sufficient safety and efficacy of its product candidates in its clinical trials; uncertainties related to the success of later-stage clinical trials, regardless of the outcomes of preclinical testing and early-stage trials; market acceptance of Allakos’ product candidates; uncertainties related to the projections of the size of patient populations suffering from the diseases Allakos is targeting; Allakos’ ability to advance additional product candidates beyond lirentelimab; Allakos’ ability to obtain additional capital to finance its operations; and other important risk factors set forth in Allakos’ most recent Annual Report on Form 10-K filed with the SEC on March 1, 2021, Quarterly Report on Form 10-Q filed with the SEC on May 10, 2021, and future reports to be filed with the SEC. These documents contain and identify important factors that could cause the actual results for Allakos to differ materially from those contained in Allakos’ forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Allakos specifically disclaims any obligation to update any forward-looking statement, except as required by law. These forward-looking statements should not be relied upon as representing Allakos’ views as of any date subsequent to the date of this press release. Source: Allakos Inc. Investor Contact: Media Contact:Adam Tomasi, President and COO Denise Powellir@allakos.com denise@redhousecomms.com ALLAKOS INC. STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except per share data) Three Months Ended March 31, 2021 2020 Operating expenses Research and development $38,915 $18,285 General and administrative 16,670 11,588 Total operating expenses 55,585 29,873 Loss from operations (55,585) (29,873)Interest income 130 1,989 Other income (expense), net (103) 60 Net loss (55,558) (27,824)Unrealized gain on marketable securities 80 1,869 Comprehensive loss $(55,478) $(25,955)Net loss per common share: Basic and diluted $(1.04) $(0.57)Weighted-average number of common shares outstanding: Basic and diluted 53,186 48,691 ALLAKOS INC. CONDENSED BALANCE SHEETS (in thousands) March 31, December 31, 2021 2020 Assets Current assets: Cash and cash equivalents $169,989 $207,177 Investments in marketable securities 445,945 451,820 Prepaid expenses and other current assets 13,015 10,270 Total current assets 628,949 669,267 Property and equipment, net 13,620 8,345 Operating lease right-of-use assets 38,924 39,731 Other long-term assets 2,275 2,275 Total assets $683,768 $719,618 Liabilities and stockholders’ equity Current liabilities: Accounts payable $9,911 $13,960 Accrued expenses and other current liabilities 12,976 8,490 Total current liabilities 22,887 22,450 Operating lease liabilities, net of current portion 44,827 42,773 Total liabilities 67,714 65,223 Stockholders’ equity: Common stock 53 53 Additional paid-in capital 1,014,435 997,298 Accumulated other comprehensive gain 88 8 Accumulated deficit (398,522) (342,964)Total stockholders’ equity 616,054 654,395 Total liabilities and stockholders’ equity $683,768 $719,618

  • Allakos Appoints Baird Radford as Chief Financial Officer
    GlobeNewswire

    Allakos Appoints Baird Radford as Chief Financial Officer

    REDWOOD CITY, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced that Baird Radford has been appointed Chief Financial Officer. As CFO, Mr. Radford will lead Allakos’ finance organization while working with the Company’s leadership team to drive its strategic initiatives and operating principles. Mr. Radford has over 25 years of finance and leadership experience at public companies in multiple industries and various stages of growth. Prior to joining Allakos, Mr. Radford served as Senior Vice President of Finance at Aimmune Therapeutics where he was responsible for all aspects of strategic and operational finance activities supporting the launch of its first approved product, including financial planning, controllership, tax and treasury functions. Prior to working at Aimmune Therapeutics, he served as the Chief Financial Officer at HeartFlow and held senior finance positions at Intuitive Surgical, eBay and PricewaterhouseCoopers. Mr. Radford received his Bachelor of Business Administration from Ohio University. “We are extremely pleased to have Baird join the Allakos team–he is a proven executive who has shaped and led successful teams. Baird brings broad experience and a track record of success at commercial-stage companies as we position Allakos for growth and potential commercialization of our first product candidate,” said Robert Alexander, PhD, chief executive officer of Allakos. “We look forward to leveraging Baird’s expertise as we enter the next critical phase of our growth.” "With lirentelimab in a Phase 3 pivotal study, this is an exciting time to be joining Allakos," said Mr. Radford. "I am honored to be part of the Allakos team and look forward to helping the company achieve its strategic objectives and financial goals as we work together to address the need for safe and effective therapies for eosinophil and mast cell-related diseases.” About Allakos Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company’s lead antibody, lirentelimab (AK002), is being evaluated in a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and a Phase 2/3 study in eosinophilic esophagitis (EoE). Lirentelimab targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Lirentelimab has been tested in multiple clinical studies. In these studies, lirentelimab eliminated blood and tissue eosinophils, inhibited mast cells and improved disease symptoms in patients with EG and/or EoD, EoE, mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria and indolent systemic mastocytosis. For more information, please visit the Company's website at www.allakos.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, Allakos’ progress and business plans, the expected timing of anticipated study results and plans relating to its future clinical trials. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to: Allakos’ stages of clinical drug development; Allakos’ ability to timely complete clinical trials for, and if approved, commercialize lirentelimab (AK002), its lead compound; Allakos’ ability to obtain required regulatory approvals for its product candidates; uncertainties related to the enrollment of patients in its clinical trials; Allakos’ ability to demonstrate sufficient safety and efficacy of its product candidates in its clinical trials; uncertainties related to the success of later-stage clinical trials, regardless of the outcomes of preclinical testing and early-stage trials; market acceptance of Allakos’ product candidates; uncertainties related to the projections of the size of patient populations suffering from the diseases Allakos is targeting; Allakos’ ability to advance additional product candidates beyond lirentelimab; Allakos’ ability to obtain additional capital to finance its operations; and other important risk factors set forth in Allakos’ most recent Annual Report on Form 10-K filed with the SEC on March 1, 2021, and future reports to be filed with the SEC. These documents contain and identify important factors that could cause the actual results for Allakos to differ materially from those contained in Allakos’ forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Allakos specifically disclaims any obligation to update any forward-looking statement, except as required by law. These forward-looking statements should not be relied upon as representing Allakos’ views as of any date subsequent to the date of this press release. Source: Allakos Inc. CONTACT: Investor Contact: Adam Tomasi, President & COO ir@allakos.com Media Contact: Denise Powell denise@redhousecomms.com

  • Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting
    GlobeNewswire

    Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting

    REDWOOD CITY, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the acceptance of two oral and five poster presentations at the upcoming Digestive Disease Week (DDW) Annual Meeting. The presentations will take place during the DDW Annual Meeting being held virtually from May 21 to 23, 2021, at which time ePosters and ePapers will be available from the DDW ePosters and ePapers website. Abstracts will be available on the ePosters and ePapers website in April, and in the May online supplement to Gastroenterology. Prevalence Data Presentations: Presentation (Presenter):Endoscopy and Systematic Biopsy of Patients with Chronic Gastrointestinal Symptoms Leads to High Discovery Rate of Patients Who Meet Histologic Criteria for Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Nicholas Talley MD PhD)Session (Time):Novel Insights into the Pathogenesis and Management of Eosinophilic Esophagitis and Gastroenteritis (Presentation #537, May 22, 4:00–4:14pm ET)Poster (Presenter):Gastroduodenal Eosinophilia is Under-Appreciated in Eosinophilic Esophagitis (EoE) Patients with Functional Bowel Symptoms: A Real Life Experience (Kathryn Peterson MD)Session (Time):Eosinophilic Esophagitis and Gastroenteritis: Clinical (Session #5105, May 21, 12:15–1:00pm ET) Long-Term Treatment Presentation: Presentation (Presenter):Long-Term Treatment of Patients with Eosinophilic Gastritis and/or Eosinophilic with Lirentelimab, a Monoclonal Antibody Against Siglec-8 (Kathryn Peterson MD)Session (Time):Novel Insights into the Pathogenesis and Management of Eosinophilic Esophagitis and Gastroenteritis (Presentation #539, May 22, 4:28–4:42pm ET) Mechanism of Disease Presentation: Poster (Presenter):Activated Mast Cells and Eosinophils are Associated with Increased Inflammatory Mediators in Mucosal Biopsies from Patients with Chronic Gastrointestinal Symptoms (Bradford Youngblood PhD)Session (Time):Eosinophilic Esophagitis and Gastroenteritis: Clinical (Poster of Distinction, Session #5105, May 21, 12:15–1:00pm ET) Diagnosis of EG and/or EoD Presentations: Poster (Presenter):Optimization of Eosinophilic Gastritis/Duodenitits Detection Requires Evaluation of Multiple High-Powered Fields in Each of 8 Gastric and 4 Duodenal Biopsies: Analysis from a Randomized Trial (Evan Dellon MD MPH)Session (Time):Eosinophilic Esophagitis and Gastroenteritis: Clinical (Session #5105, May 21, 12:15–1:00pm ET) Poster (Presenter):Eosinophilic Gastritis and Eosinophilic Duodenitis Exhibit a Similar Clinical Presentation, Underscoring the Need for Collection of Multiple Biopsies from Both the Stomach and Duodenum to Evaluate for Tissue Eosinophilia: Analysis from a Randomized Trial (Nirmala Gonsalves MD)Session (Time):Eosinophilic Esophagitis and Gastroenteritis: Clinical (Session #5105, May 21, 12:15–1:00pm ET) Poster (Presenter):Endoscopic Appearance Does Not Predict the Presence of Histologic Eosinophilic Gastritis Among Symptomatic Adults, Indicating that Collection and Evaluation of Biopsies Should Occur Regardless of Endoscopic Appearance: Analysis from a Randomized Trial (Ikuo Hirano MD)Session (Time):Eosinophilic Esophagitis and Gastroenteritis: Clinical (Session #5105, May 21, 12:15–1:00pm ET) Following the presentations, the posters and slides will be available on the Allakos website. About Allakos Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company’s lead antibody, lirentelimab (AK002), is being evaluated in a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and a Phase 2/3 study in eosinophilic esophagitis (EoE). Lirentelimab targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Lirentelimab has been tested in multiple clinical studies. In these studies, lirentelimab eliminated blood and tissue eosinophils, inhibited mast cells and improved disease symptoms in patients with EG and/or EoD, EoE, mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria and indolent systemic mastocytosis. For more information, please visit the Company's website at www.allakos.com. Source: Allakos Inc. CONTACT: Investor Contact: Adam Tomasi, President, COO & CFO ir@allakos.com Media Contact: Denise Powell denise@redhousecomms.com